Investor Presentaiton
Royalty Pharma non-GAAP financial measures
$ in millions
Royalty receipts
Distributions to non-controlling interests
FY 2021
FY 2020
2,609
2,344
(480)
(544)
Adjusted Cash Receipts (non-GAAP) (1)
2,129
1,800
Payments for operating and professional costs
(185)
(180)
Adjusted EBITDA (non-GAAP)(1)
1,944
1,621
Development-stage funding payments - ongoing
(7)
(20)
Development-stage funding payments - upfront & milestones
(193)
(6)
Interest paid, net
(127)
(95)
Investments in equity method investees
(35)
(40)
Other
(16)
10
10
Contributions from non-controlling interests - R&D
7
8
Adjusted Cash Flow (non-GAAP)(1)
1,573
1,477
Amounts may not add due to rounding
ROYALTY PHARMA
110
(1) Refer to slide 114 for definitions. Refer to Royalty Pharma's Current Reports on Form 8-K filed with the SEC on February 15, 2022 and May 5, 2022 for additional discussion.View entire presentation